T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

NCT02153905 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Slow, insufficient accrual.

Conditions

Breast Cancer
Cervical Cancer
Renal Cancer
Melanoma
Bladder Cancer

Interventions

DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)

Sponsor

National Cancer Institute (NCI)